CR20140334A - Forma galénica divisible que permite una liberación modificada del principio activo - Google Patents

Forma galénica divisible que permite una liberación modificada del principio activo

Info

Publication number
CR20140334A
CR20140334A CR20140334A CR20140334A CR20140334A CR 20140334 A CR20140334 A CR 20140334A CR 20140334 A CR20140334 A CR 20140334A CR 20140334 A CR20140334 A CR 20140334A CR 20140334 A CR20140334 A CR 20140334A
Authority
CR
Costa Rica
Prior art keywords
divisible
allows
modified release
active principle
galenic form
Prior art date
Application number
CR20140334A
Other languages
English (en)
Inventor
Gilles Fonknechten
Patrick Genty
Jean-Manuel Pean
Patrick Wuthrich
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39796790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140334(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CR20140334A publication Critical patent/CR20140334A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Una forma galénica divisible de liberación modificada de principio activo.
CR20140334A 2008-03-21 2014-07-10 Forma galénica divisible que permite una liberación modificada del principio activo CR20140334A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0801561A FR2928836B1 (fr) 2008-03-21 2008-03-21 Forme galenique secable permettant une liberation modifiee du principe actif

Publications (1)

Publication Number Publication Date
CR20140334A true CR20140334A (es) 2014-08-20

Family

ID=39796790

Family Applications (2)

Application Number Title Priority Date Filing Date
CR10317A CR10317A (es) 2008-03-21 2008-09-24 "forma galenica divisible que permite una liberacion modificada del principio activo"
CR20140334A CR20140334A (es) 2008-03-21 2014-07-10 Forma galénica divisible que permite una liberación modificada del principio activo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR10317A CR10317A (es) 2008-03-21 2008-09-24 "forma galenica divisible que permite una liberacion modificada del principio activo"

Country Status (35)

Country Link
US (3) US20090238870A1 (es)
EP (2) EP2103302A1 (es)
JP (2) JP5231906B2 (es)
KR (3) KR20090101048A (es)
CN (1) CN101347414B (es)
AP (1) AP2729A (es)
AR (1) AR067993A1 (es)
AU (1) AU2008207680B8 (es)
CA (1) CA2629670C (es)
CL (1) CL2008002486A1 (es)
CO (1) CO6020017A1 (es)
CR (2) CR10317A (es)
CU (1) CU23970B1 (es)
EA (1) EA200801862A1 (es)
EC (1) ECSP088727A (es)
FR (1) FR2928836B1 (es)
GT (1) GT200800163A (es)
HN (1) HN2008001466A (es)
IL (1) IL193611A0 (es)
JO (1) JO3052B1 (es)
MA (1) MA31218B1 (es)
ME (1) ME01031B (es)
MX (1) MX2008011579A (es)
MY (1) MY150660A (es)
NI (1) NI200800256A (es)
NZ (1) NZ570715A (es)
PE (1) PE20090991A1 (es)
SA (1) SA08290555B1 (es)
SG (1) SG155819A1 (es)
SV (1) SV2008003023A (es)
TW (1) TWI396561B (es)
UA (1) UA86731C2 (es)
UY (1) UY31307A1 (es)
WO (1) WO2009125087A1 (es)
ZA (1) ZA200807354B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007048219A2 (en) 2005-09-09 2007-05-03 Labopharm Inc. Sustained drug release composition
US20070160960A1 (en) * 2005-10-21 2007-07-12 Laser Shot, Inc. System and method for calculating a projectile impact coordinates
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TR201103946A1 (tr) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan gliklazid formülasyonları.
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ITFI20130184A1 (it) 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN106892856A (zh) * 2017-02-06 2017-06-27 山东科源制药股份有限公司 一种格列齐特粗品重结晶的制备方法
ES3010208T3 (en) * 2020-03-16 2025-04-01 Gruenenthal Gmbh Scored tablet comprising tapentadol

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
US4353887A (en) * 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
JPH069375A (ja) * 1992-04-10 1994-01-18 Takeda Chem Ind Ltd 分割可能な連結錠剤
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
AU738804B2 (en) * 1997-12-08 2001-09-27 Bristol-Myers Squibb Company Novel salts of metformin and method
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
JP2006052230A (ja) * 1998-04-03 2006-02-23 Kyowa Hakko Kogyo Co Ltd 分割錠剤及びプレススルーパック
ES2302364T3 (es) * 1998-04-03 2008-07-01 Kyowa Hakko Kogyo Co., Ltd. Tableta divisible y paquete perforado por presion.
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
EP1169024B1 (en) * 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
DE10117208A1 (de) * 2001-04-06 2002-10-10 Wolff Walsrode Ag Verfahren zur Herstellung von niederviskosen, wässrigen Celluloseetherlösungen
CN1294908C (zh) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 口服格列齐特缓释制剂
AU2004318976B2 (en) * 2004-04-29 2009-04-09 Lotus Pharmaceutical Co., Ltd. Oral modified-release lozenges and their preparation method
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
WO2006061697A1 (en) * 2004-12-06 2006-06-15 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
DE102005014141B4 (de) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablettenförmige Retardzubereitung gegen Schwindel
ES2545589T3 (es) * 2005-04-08 2015-09-14 Abbott Laboratories Formulaciones farmacéuticas orales que comprenden sales de ácido fenofíbrico
EP3205337A1 (en) * 2005-08-18 2017-08-16 Teijin Pharma Limited Formulation having accurate dose-dividing function
JP5046501B2 (ja) * 2005-08-18 2012-10-10 帝人ファーマ株式会社 複数の薬物を分離して保持する錠剤
WO2007048219A2 (en) * 2005-09-09 2007-05-03 Labopharm Inc. Sustained drug release composition
BRPI0616694B8 (pt) * 2005-09-29 2021-05-25 Novartis Ag processo para preparar comprimido farmacêutico com 80 e 96% em peso com base no peso seco de vildagliptina e metformina ou seus sais farmaceuticamente aceitáveis
EA016728B1 (ru) * 2006-08-10 2012-07-30 Такеда Фармасьютикал Компани Лимитед Фармацевтическая композиция
WO2008062470A2 (en) * 2006-10-19 2008-05-29 Torrent Pharmaceuticals Limited Stabilized controlled release dosage form of gliclazide
JP2008208078A (ja) * 2007-02-27 2008-09-11 Takada Seiyaku Kk 分割錠剤

Also Published As

Publication number Publication date
ZA200807354B (en) 2008-11-26
HN2008001466A (es) 2011-04-25
AU2008207680B8 (en) 2010-05-13
KR101693189B1 (ko) 2017-01-05
HK1127280A1 (en) 2009-09-25
AR067993A1 (es) 2009-10-28
AU2008207680A1 (en) 2009-10-08
IL193611A0 (en) 2009-08-03
EP3025706A1 (fr) 2016-06-01
EA200801862A1 (ru) 2009-10-30
KR20110112266A (ko) 2011-10-12
EP2103302A1 (fr) 2009-09-23
US20130295176A1 (en) 2013-11-07
BRPI0803631A2 (pt) 2011-03-29
KR20150035829A (ko) 2015-04-07
SA08290555B1 (ar) 2011-07-20
MA31218B1 (fr) 2010-03-01
NZ570715A (en) 2010-10-29
US20140221449A1 (en) 2014-08-07
NI200800256A (es) 2010-02-11
ME01031B (me) 2012-10-20
TWI396561B (zh) 2013-05-21
GT200800163A (es) 2010-05-21
CN101347414B (zh) 2011-11-23
JP2010209103A (ja) 2010-09-24
JP2009227651A (ja) 2009-10-08
UA86731C2 (ru) 2009-05-12
MX2008011579A (es) 2009-09-21
WO2009125087A1 (fr) 2009-10-15
CA2629670A1 (fr) 2008-10-01
CR10317A (es) 2008-11-26
CN101347414A (zh) 2009-01-21
UY31307A1 (es) 2008-10-31
FR2928836A1 (fr) 2009-09-25
PE20090991A1 (es) 2009-07-18
CO6020017A1 (es) 2009-03-31
AU2008207680B2 (en) 2010-04-22
TW200940109A (en) 2009-10-01
ECSP088727A (es) 2008-10-31
US20090238870A1 (en) 2009-09-24
AP2729A (en) 2013-08-31
SV2008003023A (es) 2010-07-29
MY150660A (en) 2014-02-14
JO3052B1 (ar) 2017-03-15
SG155819A1 (en) 2009-10-29
JP5231906B2 (ja) 2013-07-10
AP2008004614A0 (en) 2008-10-31
CU20080179A7 (es) 2011-04-26
FR2928836B1 (fr) 2011-08-26
CU23970B1 (es) 2013-12-27
CL2008002486A1 (es) 2008-12-26
KR20090101048A (ko) 2009-09-24
CA2629670C (fr) 2012-04-17

Similar Documents

Publication Publication Date Title
CR20140334A (es) Forma galénica divisible que permite una liberación modificada del principio activo
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CR20110002S (es) Barra de chocolate
PT2435025T (pt) Administração, por via respiratória, de agentes activos
EP2317984A4 (en) ARTICLE FOR THE RELEASE OF AN ACTIVE SUBSTANCE
BRPI0912431A2 (pt) Combinações de substâncias ativas sinergísticas
BRPI0818874A2 (pt) Liberação de agentes ativos
BRPI1014956A2 (pt) agentes antinflamatórios.
BRPI1008498A2 (pt) Composto, prodroga do composto, medicamento, e, uso de um composto.
EP2340038A4 (en) BIOCHEMICALLY STABILIZED HIV-1 ENV TRIMER VACCINE
BRPI0912252A2 (pt) dispositivos oftálmicos para liberação controlada de agentes ativos.
LT3360575T (lt) Transderminės farmacinės kompozicijos, apimančios veiksminguosius agentus
BRPI0922464A2 (pt) Combinações de compostos ativos
IT1390737B1 (it) Macchina per la realizzazione di articoli assorbenti.
CY1117163T1 (el) Ιμιδαζοπυριδαζινες ως αναστολεις κινασης ακτ
CL2015000091A1 (es) Apósitos con una liberación prolongada de agentes activos.
IT1392575B1 (it) Amplificatore con combinatore di potenza differenziale, a trasformatore attivo distribuito
BRPI0908722A2 (pt) reformadora ativa
CL2009001973S1 (es) Mostrador.
FR2980955B1 (fr) Compositions desinfectantes et detergentes.
BRPI0921225A2 (pt) caixinha porta-remédio e seu uso.
EA201071412A1 (ru) Дронедарон для предотвращения кардиоверсии
BRPI1009090A2 (pt) composto, pró-droga, medicamento, métodos, e, uso do composto
UY34497A (es) Formas cristalinas de [(S)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida de ácido 2-(2-metilamino-pirimidin-4-il)-1H-indol-5-carboxílico.
HN2010002052S1 (es) Blanco para una llave